Geode Capital Management
NEUP

Geode Capital Management’s Neuphoria Therapeutics NEUP Stock Holding History

Geode Capital Management’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$216K Sell
49,516
-2,491
-5% -$12K ﹤0.01% 3888
2026
Q1 		$212K Buy
52,007
+34,704
+201% +$147K ﹤0.01% 3891
2025
Q4 		$67.1K Buy
17,303
+4,325
+33% +$30.7K ﹤0.01% 4183
2025
Q3 		$153K Buy
+12,978
New +$120K ﹤0.01% 4015

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Geode Capital Management's NEUP Position: Q2 2026 in Review

Geode Capital Management reduced its Neuphoria Therapeutics (NEUP) stake by 4.8% in Q2 2026, selling an estimated $12K and leaving 49,516 shares worth $216K. The position accounts for ﹤0.01% of the portfolio, ranked #3888.

Geode Capital Management first reported a position in NEUP in Q3 2025 and has held it in 4 quarters since. 22 funds tracked by Wall St. Rank hold NEUP as of Q2 2026.

  • Geode Capital Management held 49,516 shares of Neuphoria Therapeutics worth $216K as of Q2 2026.
  • Geode Capital Management sold 2,491 Neuphoria Therapeutics shares in Q2 2026, an estimated $12K.
  • Neuphoria Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3888 holding.
  • Geode Capital Management first reported a position in Neuphoria Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 22 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.